“ambr15 for cell culture process optimization” Webinar 3P Biopharmaceuticals and Sartorius Stedim Biotech

“ambr15 for cell culture process optimization” Webinar 3P Biopharmaceuticals and Sartorius Stedim Biotech

Did you miss our webinar about our experience using ambr® 15 with CHO-S cell line for the production of monoclonal antibodies?

High-throughput media and feed screening for cell culture process optimization with multi-parallel micro bioreactors

Watch it now!

In the development and delivery of high quality therapeutic proteins, high throughput process development tools can really accelerate early process understanding.

ambr® 15 cell culture system offers an alternative approach to shake flask or conventional benchtop bioreactors in an automated, multi-parallel, high throughput format. The system can be implemented within the Upstream process workflow to generate early process development data at the small scale with very low demands on operator time, set-up and turn around due to automation and single-use components, and improve global costs of development due to the minimum scale the equipment is designed to operate.

In this webinar Dr Marta Ruiz Guillén, USP development expert at 3P Biopharmaceuticals, and Javier Lobo, Field Marketing Manager for Sartorius Stedim Biotech in Latin America, Spain & Portugal; discuss the methods and results from performing media and feed screening evaluations in ambr® 15 with CHO-S cell line producing monoclonal antibodies and demonstrate the effectiveness of ambr 15 for rapid and robust cell culture process development.

Watch it now and learn more about the experiments performed:

  • Screening of different media
  • Evaluation of different feeds
  • Effect of supplements
  • Optimization of feed strategy

Our dedicated team of specialists will be happy to discuss any of your Biopharmaceutical Manufacturing needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2

Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19
Read more

Elena Erroba, winner of the Navarra 2021 Management Award organised by AMEDNA-NEEZE

Elena Erroba, Director of Business Development, Communication and Marketing at 3P Biopharmaceuticals, has been elected as Navarra’s Businesswoman of the Year 2021
Read more

3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA

The investments will enable the company to increase its mammalian cell-based protein production capacity tenfold and increase its microbial cell-based protein production capacity by 50%. The total floor space of the company will triple.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.